Avet Pharma Announces the Launch of Verapamil 40mg
Eatontown, NJ, December 3, 2015. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Verapamil 40mg immediate-release tablets. This launch adds to Avet’s robust portfolio of generic oral solid products, and provides Avet with all three strengths of Verapamil (40, 80 and 120mg).
Verapamil is the AB rated generic equivalent to the calcium channel blocker drug Calan®*. It is indicated for the treatment of angina, arrhythmias and essential hypertension. According to IMS data for the twelve-months ended October 2015, the U.S. market for Verapamil 40mg immediate-release tablets is approximately $1.95 million.